Q-omics provides the consensus-scored MRPS7 profile across patient tissues and cancer cell-line models. MRPS7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPS7 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MRPS7 protein abundance shows 21,068 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where MRPS7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS7 survival associations across molecular data types. MRPS7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS7 RNA expression–survival associations across cancer types. High MRPS7 expression shows unfavorable associations in UVM, ACC, KICH, HNSC, LIHC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPS7 RNA expression.
This table summarizes MRPS7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS7 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and KIRP. The HNSC box plot shows higher MRPS7 RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with MRPS7 in patient tissues and cancer cell lines. In patient samples, MRPS7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
